Introduction {#sec1}
============

Parkinson\'s disease (PD) is a progressive neurodegenerative movement disorder distinguished neuropathologically by the presence of Lewy bodies and Lewy neurites---proteinaceous cytoplasmic inclusions---in dopaminergic neurons of the *substantia nigra* ([@bib1]). Electron microscopy shows these inclusions to be composed of amyloid-like fibrillar material, the major component of which is the 140-residue, intrinsically disordered protein *α*-synuclein (*α*Syn) ([@bib2]). Recombinant *α*Syn has been found to form aggregates in vitro with all the characteristics of amyloid fibrils associated with diseased states ([@bib3]). Although most cases of PD are idiopathic, a small number of familial forms have been identified including the A53T variant, in which aggregation is significantly accelerated relative to the wild-type (WT) ([@bib4]), thus implicating *α*Syn aggregation in the etiology of PD. As *α*Syn knockout mice do not exhibit PD-like symptoms, it can be concluded that PD results from a pathological gain of function (i.e., aggregate toxicity) rather than the loss of normal *α*Syn function ([@bib5]).

The aggregation mechanism itself, in common with other amyloid systems, is a nucleated process in which there is slow and initially unfavorable association of monomers into a structure competent to elongate into full-length fibrils ([@bib6]). An important experimental consequence of such a nucleation-polymerization mechanism is the phenomenon of seeding, in which a substoichiometric quantity of preformed fibrils can greatly accelerate the aggregation reaction by bypassing the nucleation process. The aggregation kinetics of seeded reactions are therefore determined only by the elongation and fragmentation rates, and, in the initial rate approximation, by the elongation rate alone ([@bib7]).

*α*Syn aggregation may be suppressed by the molecular chaperone Hsp70, and biophysical investigations have shown that this inhibition occurs via binding to prefibrillar species rather than monomeric *α*Syn ([@bib8]). Another molecular chaperone that inhibits *α*Syn aggregation is *α*B-crystallin, a 175-residue protein ubiquitous in mammalian tissue ([@bib9]). Early work showed that *α*B-crystallin is a member of the family of small heat shock proteins (sHsps), and is upregulated in response to a range of stress stimuli and clinical disorders including Alzheimer\'s disease, transmissible spongiform encephalopathies, dementia with Lewy bodies, and Parkinson\'s disease ([@bib10]). As a sHsp, *α*B-crystallin is a molecular chaperone and has been demonstrated to suppress thermally induced aggregation of *β*- and *γ*-crystallins, suggesting that it acts as a significant protective mechanism against cataract formation in the eye lens ([@bib11]); the latter is associated with aggregation and has been shown in some cases to involve amyloid formation ([@bib12]). *α*B-Crystallin also inhibits the aggregation of several other proteins in vitro, including the amyloid-*β* peptides, *β*~2~-microglobulin, and insulin ([@bib13; @bib14]). There are, however, conflicting reports as to whether such inhibition is neuroprotective ([@bib15; @bib16]).

The sequence of *α*B-crystallin has amphipathic character, and contains a hydrophobic N-terminal domain, a central *α*-crystallin domain (common to all sHsps), and a hydrophilic and flexible 12-residue C-terminal extension ([@bib9]). The amphipathic nature of the sequence is believed to be crucial to its chaperone function, enabling *α*B-crystallin to bind to exposed hydrophobic patches characteristic of misfolded states ([@bib17]). The hydrophilic and highly flexible C-terminal extension, as characterized by solution state nuclear magnetic resonance (NMR) ([@bib18]), is also essential to efficient chaperone activity, with an important role in solubilizing complexes of the chaperone with misfolded and aggregated species ([@bib10]). No crystal structure of *α*B-crystallin has yet been determined; comparison of the *α*-crystallin domain with structures of other sHsps, however, suggests that the central domain will adopt a *β*-sandwich structure ([@bib19]). A major barrier to structural characterization of *α*B-crystallin, and certainly to its crystallization, is the self-association of monomers into large, polydispersed assemblies (typically 24--33mers), with molecular masses varying from 300 kDa to \>1 MDa ([@bib20]). Studies of the quaternary structure of the protein by cryo-electron microscopy reveal spherical assemblies between 8 and 18 nm in diameter with a central cavity ([@bib21]), which undergo subunit exchange on a timescale of minutes ([@bib22]). This exchange is inhibited by binding to large denatured or partially unfolded proteins, suggesting that subunit exchange may have an important role in the mechanism of chaperone action ([@bib10; @bib22]).

*α*B-Crystallin accumulates in neurons and glia of the central nervous system under pathological conditions ([@bib23]), becoming colocalized with *α*Syn in Lewy bodies along with a host of other proteins including the sHsp Hsp27, and other chaperones such as clusterin, Hsp70, and Hsp90 ([@bib24]). In vitro biophysical studies demonstrated complete inhibition of the nucleated assembly of *α*Syn into fibrils by 0.25 equivalents of *α*B-crystallin ([@bib25]). Imaging studies of the aggregation products showed large amounts of amorphous material, which was interpreted as the binding of *α*B-crystallin to monomeric or oligomeric intermediates, inhibiting the nucleation of fibrillar *α*Syn aggregates. Later studies additionally demonstrated that the addition of 0.5 equivalents of *α*B-crystallin to aggregating samples of *α*Syn is highly effective in inhibiting further growth, and this was also interpreted as a consequence of the stabilization of monomeric or prefibrillar *α*Syn, inhibiting its incorporation into the growing fibril ([@bib26]).

Given the complex mechanisms of amyloid formation and the number of aggregated species involved---e.g., monomers, oligomers, protofibrils, fibrils, and amorphous assemblies---we were motivated to consider the interaction of *α*B-crystallin with additional species along the aggregation pathway and, in particular, with the mature fibrils themselves, which hitherto have largely been regarded as inert reaction products. There is evidence, however, that this view might not be correct, as *α*B-crystallin has been reported to bind to A*β*40 fibrils, and it has been suggested that this interaction may inhibit further aggregation ([@bib13]), although the experimental data reported could not conclusively distinguish between the effects of the chaperone in solution or bound to the fibril. A separate study of insulin aggregation at low pH demonstrated that fibril elongation is inhibited after the incubation of the insulin fibrils with *α*B-crystallin, where the detection of binding stimulated the proposal that the latter serves to limit further fibril growth ([@bib14]). Here we investigate the hypothesis that *α*B-crystallin might bind to *α*Syn fibrils, and use a variety of techniques including newly developed QCM and NMR methodologies to explore the range of effects that result from such chaperone-fibril interactions.

Materials and Methods {#sec2}
=====================

These are described in the [Supporting Material](#app2){ref-type="sec"}.

Results {#sec3}
=======

Characterization of *α*Syn interactions with *α*B-crystallin {#sec3.1}
------------------------------------------------------------

The cosedimentation of *α*B-crystallin and two control proteins (green fluorescent protein, GFP, and ubiquitin hydrolase, UCH-L3) with preformed A53T *α*Syn fibrils was assayed by SDS-PAGE ([Fig. 1](#fig1){ref-type="fig"} *A*). A53T *α*Syn was chosen for this study because of its high aggregation propensity relative to the WT protein ([@bib4]), and it was found to pellet *α*B-crystallin in a similar manner to that previously observed for the WT ([@bib25]). The intensity of staining with Coomassie blue was used to estimate the amount of *α*B-crystallin present in the pelleted fraction ([Fig. S1](#app2){ref-type="sec"} *A* in the [Supporting Material](#app2){ref-type="sec"}), and an approximate binding ratio of 0.6:1 *α*B-crystallin:*α*Syn was determined, where the latter refers to the concentration of the constituent monomers within the fibrils and the observed staining intensity was normalized by protein mass. The corresponding binding ratios for GFP and UCH-L3 were 0.1:1 and 0.01:1, respectively, both consistent with residual material expected from the incomplete washing of the pellet, and indicating that the sedimentation of *α*B-crystallin was not due to any generic affinity of proteins for hydrophobic patches on the fibril surface, or rheological effects from the fibril network during centrifugation. *α*B-Crystallin alone was not observed to sediment under these conditions ([Fig. S1](#app2){ref-type="sec"}, *B* and *C*).

The intrinsic tryptophan fluorescence of *α*B-crystallin was used to estimate the concentration of the protein remaining in solution after incubation with preformed A53T fibrils and centrifugation for 30 min at 16,000 × *g* ([Fig. 1](#fig1){ref-type="fig"} *B*); these conditions were found sufficient to pellet *α*Syn fibrils completely, and as *α*Syn does not contain any tryptophan residues, it exhibits little intrinsic fluorescence. Only a small (6%) though reproducible enhancement of *α*B-crystallin fluorescence was detected in the presence of monomeric *α*Syn ([Fig. 1](#fig1){ref-type="fig"} *B*), with a concomitant blue-shift of 1 nm (343--342 nm) indicative of the fluorophore being in a more hydrophobic environment, and consistent with the existence of a weak interaction between *α*B-crystallin and monomeric *α*Syn ([@bib25]).

To investigate its putative interaction with monomeric *α*Syn further, *α*B-crystallin was titrated into uniformly ^15^N-labeled *α*Syn, and changes in the amide chemical shifts were monitored by recording \[^1^H,^15^N\]-HSQC experiments ([Fig. S2](#app2){ref-type="sec"}). Few significant changes were observed, and the largest perturbation, at His^50^, can be attributed to its high sensitivity to small changes in pH, an observation noted previously in titrations of monomeric *α*Syn ([@bib8]). A small, uniform increase in signal intensity was observed, in contrast to previous reports of a uniform loss of intensity ([@bib25]). This finding suggests that these changes are more probably attributable to the effect of slight pH changes on amide exchange broadening than to the association of *α*Syn and *α*B-crystallin. Thus, whereas measurements of tryptophan fluorescence imply that some interaction exists between the proteins, the NMR results reported both here and previously ([@bib25]) together suggest that this is only transient and of low affinity, similar perhaps to that characterized between *α*B-crystallin and the amyloid-*β* peptide ([@bib27]). For these reasons, these interactions have not been explored further in this work.

The fluorescence assay was then used to measure the concentration of *α*B-crystallin remaining in solution after precipitation by the addition of *α*Syn fibrils at two concentrations. A precise determination of the stoichiometry or affinity of the interaction between the sHsp and fibrils is complicated by the effect of the interaction of *α*Syn monomer with *α*B-crystallin, as discussed above, and Rayleigh scattering resulting from the small number of *α*Syn fibrils that remain in solution after centrifugation. In addition, allowance had to be made for the effect of *α*B-crystallin on the monomer-fibril equilibrium (discussed later) and hence on the absolute fibril concentration. For these reasons, an exact analysis has not been attempted, but it was observed that binding is proportional to the fibril concentration, and an approximate ratio of 0.23 ± 0.06 bound *α*B-crystallin monomers per *α*Syn monomer was calculated. This value is expected to be a lower bound, with an absolute uncertainty greater than the quoted standard deviation of the observations, because of the factors discussed above. It is, however, of a comparable order of magnitude to that estimated by densitometry ([Fig. S1](#app2){ref-type="sec"} *A*).

The binding ratios determined above may be restated in terms of the available fibril surface area, using a toy model (described in [Materials and Methods](#sec2){ref-type="sec"}; see [Supporting Material](#app2){ref-type="sec"}) in which the *α*B-crystallin-fibril interaction is approximated as hard spheres of *α*B-crystallin monomers packing onto a cylindrical fibril surface. Although there is evidence that the active subunits of *α*B-crystallin may be dimeric ([@bib28]), provided that both monomers within any such dimers interact with the fibril surface, we expect that this simple model of monomeric binding will remain approximately applicable. Such an analysis determines an approximate maximum binding ratio of 0.90 ± 0.29 *α*B-crystallin monomers per *α*Syn monomer, hence the values determined by fluorescence and densitometry correspond to surface coverages of approximately 26 ± 11% and 62 ± 20%, respectively. Such high values require that the chaperone must bind to the overall surface of the *α*Syn fibrils, and not just to the small number of fibril ends.

Inhibition of fibril elongation observed by in situ ThT fluorescence {#sec3.2}
--------------------------------------------------------------------

Previous studies have examined the effect of *α*B-crystallin on the sigmoidal kinetics characteristic of nucleated polymerization (and fragmentation) reactions associated with the conversion of *α*Syn into amyloid fibrils ([@bib25; @bib26]). Such reactions are typically highly stochastic, however, and their quantitative interpretation in terms of individual microscopic processes and rates is complex ([@bib7]). To simplify the kinetic analysis in this work, preformed fibrils were used to seed the aggregation reaction in order that the elongation step alone could be examined. A series of seeded aggregation experiments were performed in which the initial elongation velocities were determined as a function of the concentration of *α*B-crystallin ([Fig. 2](#fig2){ref-type="fig"} *A*). These data show clearly that fibril growth was inhibited at low micromolar concentrations of *α*B-crystallin. Fitting to a sigmoidal dose-response curve determined the IC~50~ (the concentration of *α*B-crystallin for half-maximal inhibition) to be 335 ± 86 nM, although some dependence on the seed concentration may also be discerned, which shall be discussed later in this article.

To identify whether or not the inhibition observed above resulted from the binding of chaperone to *α*Syn in fibrils or free in solution, fibrils were preincubated with *α*B-crystallin then pelleted, washed, resuspended, and used to seed solutions of monomeric *α*Syn. [Fig. 2](#fig2){ref-type="fig"} *B* plots the resultant kinetic profiles, and shows that elongation of chaperone-bound fibrils was significantly inhibited (∼70-fold) relative to untreated fibrils, by analysis of the initial rates. The residual concentration of *α*B-crystallin after pelleting and washing was estimated to be ≤35 nM. This is an order-of-magnitude below the IC~50~ and therefore not by itself sufficient to inhibit elongation, as indicated by the marker in [Fig. 2](#fig2){ref-type="fig"} *A*. We therefore conclude that the observed inhibition of elongation results from the specific interaction of *α*B-crystallin with the *α*Syn seed fibrils.

Inhibition of fibril elongation observed with a quartz crystal microbalance {#sec3.3}
---------------------------------------------------------------------------

To verify the model of inhibition discussed above, an independent technique utilizing a quartz crystal microbalance (QCM) was employed. QCM is a technique in which the mass deposited on the surface of a quartz crystal oscillator may be determined directly via measurement of the frequency of oscillation, and recently the method has been applied to the study of amyloid growth by measuring the change in mass of growing fibrils attached to the surface ([@bib14]). Importantly, this technique enables us to examine the elongation phase of fibril growth in isolation to other processes such as nucleation, and this has been used to determine the elongation kinetics of insulin fibrils grown at low pH, demonstrating the inhibition of their elongation by *α*B-crystallin ([@bib14]). In contrast to insulin fibrils, *α*Syn fibrils did not adsorb directly onto the sensor surface, and instead were covalently attached via lysine side chains, as described in [Materials and Methods](#sec2){ref-type="sec"} (see [Supporting Material](#app2){ref-type="sec"}). A surface prepared in this manner is shown in [Fig. 3](#fig3){ref-type="fig"} *A*, and the fibrils were observed to reproducibly elongate when incubated with monomeric *α*Syn ([Fig. 3](#fig3){ref-type="fig"} *B*). Elongation was readily determined to be proportional to the monomer concentration ([Fig. S3](#app2){ref-type="sec"}), as previously observed by solution-state measurements ([@bib6]), implying that the presence of the surface does not significantly alter the elongation mechanism.

[Fig. 3](#fig3){ref-type="fig"} *C* plots the change in deposited mass during a single QCM experiment. This shows firstly the increase in mass that results from the elongation of *α*Syn fibrils in the presence of *α*Syn monomer (*arrow* 1). The subsequent injection of *α*B-crystallin with *α*Syn monomer (*arrow* 2) resulted in a large increase in mass indicative of a binding interaction. After 10 min, the reaction chamber was washed thoroughly with buffer to eliminate unbound chaperone, yet upon the injection of fresh *α*Syn monomer (*arrow* 3), further elongation was inhibited approximately sevenfold. As no free *α*B-crystallin remained in solution, inhibition must have resulted from the persistent binding of the chaperone to fibrils, providing strong support for the solution-state inhibition results presented previously in [Fig. 2](#fig2){ref-type="fig"}.

A second experiment ([Fig. 3](#fig3){ref-type="fig"} *D*) confirmed this observation: on injection of *α*Syn and *α*B-crystallin, a large initial increase in mass loading was detected. In contrast to the previous experiment, this binding was allowed to saturate, and after ∼30 min a small but constant elongation rate was observed. It is perhaps noteworthy that this timescale for association is of similar magnitude to that for the subunit exchange of *α*B-crystallin ([@bib22]), and may indicate that the *α*B-crystallin subunits are the active chaperone species. Again, the observed inhibition persisted when the reaction chamber was flushed with fresh buffer. After overnight incubation of the crystallin-treated fibrils in fresh buffer, however, the ability of the fibrils to elongate was partially restored, thus demonstrating the reversibility of the fibril-crystallin interaction. But the results also imply that dissociation of the complex occurs only on a timescale of several hours, which is suggestive of a tight binding interaction.

NMR investigations of the interaction of *α*B-crystallin with *α*Syn fibrils {#sec3.4}
----------------------------------------------------------------------------

Large species such as amyloid fibrils, with masses of approximately GDa, have traditionally been assumed to be beyond the reach of solution-state NMR methods. Recent investigations have demonstrated, however, that in some cases noncore regions of fibrils have sufficient flexibility to allow us to detect sharp resonances ([@bib29]). Therefore, in a one-dimensional ^1^H NMR spectrum of *α*B-crystallin in the presence of *α*Syn fibrils, there are four components that may potentially be observed: fibrillar *α*Syn; residual *α*Syn monomers; monomeric/oligomeric *α*B-crystallin; and fibril-bound *α*B-crystallin. Residual monomeric species are key observables in the study of the thermodynamics of polymerization, and measurements designed to estimate this concentration have been used to characterize the energetics of elongation for several fibril-forming systems ([@bib30]). The ^1^H spectrum of *α*B-crystallin has previously been characterized, and reveals that in the native oligomeric complex, the final 12 residues in the C-terminal extension have sufficient mobility to be observable by solution-state NMR ([@bib18]).

Before examination of the fibril-chaperone complex, the spectrum of *α*Syn fibrils in solution was explored. [Fig. 4](#app2){ref-type="sec"} *A* shows a portion of the one-dimensional ^1^H NMR spectrum of a solution of *α*Syn fibrils (*green line*). The fibril spectrum appears almost identical to that of monomeric *α*Syn (not shown), albeit with significantly reduced intensity. Although this spectrum suggests that the bulk of the observed signal arises from residual monomers in solution rather than the fibrils, a more detailed study was nevertheless carried out using a series of pulsed-field gradient (PFG) measurements to define the effective diffusion coefficient *D*~eff~ of the species giving rise to the resonances. For monomeric proteins, *D*~eff~ is identical to the translational diffusion coefficient *D*~trans~, and its value is independent of the diffusion delay in the NMR experiment, Δ. By contrast, for very large molecular assemblies such as amyloid fibrils, *D*~eff~ can include contributions from rotational diffusion such that *D*~eff~ \> *D*~trans~ for small values of Δ ([@bib31]). *D*~eff~ is shown in [Fig. S4](#app2){ref-type="sec"} as a function of Δ for a solution containing *α*Syn fibrils, and no such variation was detected. The mean value of *D*~eff~ was 8.6(± 1.7) × 10^−11^ m^2^ s^−1^, which is entirely consistent with that expected for a small monomeric protein ([@bib32]). Thus, in contrast to other amyloid systems such as the SH3 dimer, for which fibril resonances are observable ([@bib29]), the NMR signal in [Fig. 4](#fig4){ref-type="fig"} *A* may be attributed to residual *α*Syn monomers alone.

Having examined the spectrum of isolated *α*Syn fibrils (in equilibrium with residual monomer), it is then possible to analyze their interaction with *α*B-crystallin. [Fig. 4](#fig4){ref-type="fig"} *A* shows the methyl region of the one-dimensional ^1^H NMR spectrum of the fibril-crystallin complex alongside spectra of each component in isolation. Difference spectroscopy, normalized using the internal DSS reference, reveals that the spectrum of chaperone-bound fibrils is not the sum of the original components, but that there is additional signal in the spectrum of the complex. The difference spectrum had, however, the same appearance as monomeric *α*Syn ([Fig. 4](#fig4){ref-type="fig"} *A*). A comparison of intensities in repeated experiments using independent fibril samples determined that the mean *α*Syn intensity in the presence of *α*B-crystallin is ∼50% greater than that in its absence.

To investigate these results further, PFG NMR spectra were recorded to characterize the diffusion properties of the observed resonances. To limit the contributions from rotational motion to the diffusion coefficients measured for fibril-associated species, a long (500-ms) diffusion period Δ was employed ([@bib31]). The effective diffusion coefficients *D*~eff~ for each sample are plotted in [Fig. 4](#fig4){ref-type="fig"} *B* and these data show that the diffusion of *α*B-crystallin is retarded in the presence of *α*Syn fibrils, consistent with the formation of a fibril-chaperone complex. The measured diffusion coefficients correspond, according to the Stokes-Einstein relation, to approximate hydrodynamic radii of 3.7 ± 0.4 nm and 8.6 ± 0.4 nm for free *α*Syn and *α*B-crystallin, respectively---in good agreement with previous observations ([@bib21; @bib33]). The effective diffusion coefficient of *α*B-crystallin in the presence of *α*Syn fibrils corresponds, when modeled as rotating rigid rods ([@bib31]), to a mean fibril length of 260 ± 140 nm.

The simplest interpretation of these results is that the C-terminal extension of *α*B-crystallin is not perturbed by fibril binding and remains free to tumble in solution; hence, the one-dimensional NMR spectrum is not altered in the presence of fibrils. However, diffusion is retarded, a finding consistent with the binding of *α*B-crystallin to the fibrils. The concentration of residual *α*Syn monomer is also increased in the presence of *α*B-crystallin, indicating that the monomer-fibril equilibrium is perturbed by interactions with the chaperone. Although absolute concentrations of *α*Syn monomer were not determined, the observed 50% increase in the monomer concentration corresponds to a net destabilization of 0.3 ± 0.1 kcal mol^−1^ in the free energy of fibril elongation, assuming a simple polymerization model ([@bib30]). It is recognizable that the chaperone-monomer-fibril system comprises many coupled equilibria, and that there are potentially multiple origins to the observed increase in monomer concentration. It remains, however, a notable feature of polymerization reactions that a relatively small change in the net elongation energy may still result in a large change in the partition of monomers and fibrils.

Imaging of the fibril-chaperone complex {#sec3.5}
---------------------------------------

To confirm the binding of *α*B-crystallin to *α*Syn fibrils in a more direct manner, immunoelectron microscopy was employed to visualize the fibril-crystallin complex. *α*Syn fibrils are of sufficient size that their twisted ultrastructure could be observed clearly in the electron microscope after negative staining with uranyl acetate ([Fig. 5](#fig5){ref-type="fig"} *A*). In contrast, the *α*B-crystallin oligomers are more difficult to distinguish, particularly in a multicomponent system. Samples were therefore incubated with an antibody directed against *α*B-crystallin, which was in turn stained with a secondary antibody conjugated to 10-nm gold nanoparticles. [Fig. 5](#fig5){ref-type="fig"} *B* shows a sample of *α*B-crystallin prepared in this manner and negatively stained with uranyl acetate; electron dense gold nanoparticles are observed to be colocalized with the native *α*B-crystallin assemblies. The *α*Syn fibrils shown in [Fig. 5](#fig5){ref-type="fig"} *A* were also stained with the primary and secondary antibodies by an identical protocol; no significant nonspecific or background immunolabeling was observed. An immunolabeled fibril-crystallin complex containing 0.3 equivalents of *α*B-crystallin was then imaged ([Fig. 5](#fig5){ref-type="fig"} *C*), showing, very clearly, the interaction of *α*B-crystallin along the length of the fibrils, with gold nanoparticles observed on all faces of the fibril surface including occasional binding at the fibril ends.

Discussion {#sec4}
==========

The results of this article have enabled a novel mechanism to be proposed for the inhibition of *α*Syn aggregation by the small heat-shock protein *α*B-crystallin. *α*B-Crystallin has been demonstrated to bind along the lateral surface of *α*Syn amyloid fibrils, and this interaction has been demonstrated by a range of methods to inhibit elongation effectively, with half-maximal inhibition at an *α*B-crystallin concentration of 335 ± 86 nM. Although the binding epitopes of *α*B-crystallin and the fibrils are unknown, NMR investigations have determined that the C-terminal extension of *α*B-crystallin is able to fluctuate freely even in the bound state, a finding consistent with its purported role as a solubilizing domain ([@bib18]). NMR measurements also indicated that the presence of the chaperone perturbed the monomer-fibril equilibrium, consistent with a net destabilization of the fibrils by ∼0.3 kcal mol^−1^. This may indicate that binding of *α*B-crystallin along *α*Syn fibrils weakens the interactions between adjacent *α*Syn molecules, similar to the effect of cofilin binding to actin filaments ([@bib34]), but the additional effect of a weak interaction between *α*B-crystallin and monomeric *α*Syn cannot be ruled out at this stage.

In this work, a novel methodology based on QCM measurements has been developed to monitor *α*Syn fibril elongation, in isolation from other processes such as nucleation, and without the need for added probe molecules. As has been demonstrated in studies of insulin aggregation ([@bib14]), this technique offers significant promise for the quantitative investigation of the kinetics and mechanism of *α*Syn fibril elongation. To apply this, however, methods were developed similar to those used in surface plasmon resonance to enable the gold surface to bind the fibrils. This approach is likely to be applicable to QCM measurements of other amyloid systems that do not contain accessible thiols or disulphides.

*α*B-Crystallin has previously been reported to inhibit *α*Syn aggregation, when added even at the midpoint of sigmoidal assembly curves, and it was hypothesized that the chaperone acts by stabilizing monomeric or prefibrillar species ([@bib25; @bib26]). The mechanism put forward in this study, by which *α*B-crystallin could inhibit fibril formation by binding to the fibrils and inhibiting their elongation, suggests that there may be multiple mechanisms of chaperone action. As binding is likely to occur at least in part to the hydrophobic clusters that may form in the fibrils, it is likely that *α*B-crystallin will also interact strongly with the oligomeric precursor species, an important property given their cytotoxic nature ([@bib2]).

Two mechanisms can be envisaged to rationalize the inhibition of elongation that results from the interaction of *α*Syn fibrils with *α*B-crystallin: one is a specific capping interaction of *α*B-crystallin with the fibril ends, assuming that the binding here is tighter than that along the length of the fibril; and the second involves uniform binding of *α*B-crystallin along the length of the fibril, where inhibition results from the chance occlusion of the fibril ends. In this latter binding and occlusion model, inhibition is expected to be observed only in the presence of near equimolar ratios of *α*B-crystallin and *α*Syn fibrils, and the dependence of the IC~50~ upon the seed concentration noted in [Fig. 2](#fig2){ref-type="fig"} *A* would be consistent with such a mechanism. Further investigations of the stoichiometry and affinity of the fibril-chaperone interaction will, however, be required to differentiate these models with confidence.

A key question in the study of sHsps is whether the native oligomers act as chaperones directly, or whether dissociation into subunits occurs before their binding ([@bib35]). The approximate binding ratios presented in this work would be consistent with either a relatively uniform binding of monomeric or dimeric *α*B-crystallin subunits along the fibril surfaces, or a rarer binding of the oligomers. The high surface coverage that would result from the subunit binding appears attractive as a means of explaining the efficacy of inhibition, particularly as this effect persists when the chaperone is removed from the solution after binding has occurred. Although this mechanism of inhibition has not been put forward previously, it is consistent with previous studies in which sHsp subunit exchange dynamics have been correlated to chaperone activity, in both *α*B-crystallin and its phosphorylated derivatives ([@bib22; @bib36]).

These findings present the suggestion that other sHsps may act by a similar mechanism. The Hsp20 from the bovine parasite *Babesia bovis* inhibits A*β*40 amyloid formation, and the chaperone was active only at low (10--100 nM) concentrations in which dimeric subunits were prevalent, whereas at higher chaperone concentrations, in which larger oligomers became populated, the inhibition of aggregation was no longer observed ([@bib37]). Additionally, *α*B-crystallin may bind to components of the cytoskeleton including intermediate filaments and microtubules, although electron microscopy has demonstrated that such binding occurs via the oligomeric complex rather than isolated subunits ([@bib38]). This suggests that different chaperone activities (e.g., suppressing amyloid formation, thermally induced amorphous aggregation, and cytoskeletal binding) correspond to a variety of phosphorylation or oligomerization states and binding modes. For example, lysozyme unfolding intermediates are bound by multimeric Hsp27 ([@bib39]), and whereas *α*B-crystallin activity against *α*Syn amyloid formation increases with temperature (correlating with increased subunit exchange), little variation with temperature was observed against the thermally induced amorphous aggregation of alcohol dehydrogenase and citrate synthase ([@bib40]). Phosphorylation-mimicking mutations have also been demonstrated to differentially regulate the chaperone activity of *α*B-crystallin against amyloid fibril formation and amorphous aggregation ([@bib36]). Equally, however, some of this variation may result from a degree of specificity of individual members of the sHsp family ([@bib41]).

*α*B-Crystallin has shown no evidence of ATPase or refolding activity ([@bib19]). Instead, sHsps have been proposed to bind to misfolded states before interaction with other chaperone systems, which may facilitate refolding or degradation ([@bib41]). Horwitz et al. ([@bib9]) has suggested that *α*B-crystallin in the eye lens may act as an irreversible sink for unfolded or misfolded proteins, as there is no evidence of further chaperone systems within the lens, and active protein synthesis does not occur once the lens proteins are laid down. The binding of *α*B-crystallin to *α*Syn fibrils may therefore be a protective mechanism to stem the growth of amyloid deposits before clearance by further quality control mechanisms within the cell ([@bib41]). This hypothesis is supported by a mouse model of PD expressing A53T *α*Syn, in which selective upregulation of *α*B-crystallin was observed in affected glial cells ([@bib42]). Additionally, we suggest that binding of *α*B-crystallin to fibrils may reduce their cytotoxicity by camouflaging exposed hydrophobic surfaces. This hypothesis is supported by a tissue culture model of Lewy body disease in which colocalization of *α*B-crystallin with *α*Syn deposits occurs without a reduction in the number of inclusions compared to cells not transfected with *α*B-crystallin, although there is a significant reduction in cytotoxicity ([@bib43]). Finally, as exposed fibril surfaces have been proposed to act as sites of secondary fibril nucleation ([@bib44]), the coating of *α*Syn fibrils by *α*B-crystallin could inhibit not just their elongation but further nucleation processes as well. It is also possible, however, that fibril binding by chaperones may have a deleterious role by sequestering them and reducing their efficacy in other physiological functions, e.g., interacting with misfolded monomers or oligomers, or, indeed, helping in regulation of the cytoskeleton ([@bib41]). Certainly, these findings reveal novel activities of the cellular proteostasis network, which is of growing interest in the field of systems biology, and an increasing understanding of its behavior may contribute to the rational development of therapeutic proteostasis regulators ([@bib45]).

This finding is also likely to have general relevance to other amyloid and chaperone systems. Indeed, recent work suggests that another chaperone, Hsp104, is capable of suppressing amyloid growth at many stages along the aggregation pathway, including the elongation of mature fibrils ([@bib46]). Fibril binding and inhibition of elongation by *α*B-crystallin has previously been demonstrated for the A*β*40 peptide, although no causal link was demonstrated ([@bib13]). Inhibition of *β*~2~-microglobulin elongation by *α*B-crystallin at low pH was also reported ([@bib13]), and inhibition of insulin aggregation under similar conditions has also been observed ([@bib14]). This work is therefore important in extending mechanistic studies of *α*B-crystallin to physiological conditions and, given apparent similarities in the behavior of *α*Syn, A*β*40, *β*~2~-microglobulin, and insulin, suggests a generic mechanism of *α*B-crystallin action.
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![Characterization of interactions between *α*B-crystallin and *α*Syn. (*A*) SDS-PAGE assay of the binding of *α*B-crystallin, GFP, and UCH-L3 (all 50 *μ*M) to *α*Syn fibrils (70 *μ*M), showing both soluble fractions, *S*, and pelleted fractions, *P*, after centrifugation for 30 min at 16,000 × *g*. (*B*) Intrinsic fluorescence of solutions containing *α*B-crystallin (35 *μ*M) and/or *α*Syn monomer (35 *μ*M). The spectrum of *α*Syn monomer alone has also been subtracted from that of *α*B-crystallin + *α*Syn to illustrate the 6% enhancement of *α*B-crystallin fluorescence observed in the presence of *α*Syn (\[*α*B + *α*S\] -- *α*S). Additionally, a spectrum of *α*B-crystallin remaining in solution after centrifugation with 0.5 equivalence of *α*Syn fibrils is presented (*α*B + *α*S~Fib~).](gr1){#fig1}

![Effect of *α*B-crystallin on *α*Syn aggregation kinetics. (*A*) Determination of the effective *α*B-crystallin concentration required for inhibition of seeded fibril elongation in the presence of 35 *μ*M *α*Syn monomer, as a function of varying fibril mass, given as the % seed. Data were globally fitted to a one-site binding model as described in [Materials and Methods](#sec2){ref-type="sec"} (see [Supporting Material](#app2){ref-type="sec"}). Initial rates have been normalized to *α*Syn elongation in the absence of *α*B-crystallin. The marker (☆) indicates the relative inhibition resulting from the preincubation of the fibril seed with *α*B-crystallin, observed in [Fig. 2](#fig2){ref-type="fig"}*B*, given that the estimated residual concentration of *α*B-crystallin was \<35 nM. (*B*) Seeded elongation kinetics, monitored by in situ ThT fluorescence. Samples containing 70 *μ*M *α*Syn fibrils and/or 70 *μ*M *α*B-crystallin, as indicated in the legend, were pelleted, washed, and resuspended, then used to seed fresh *α*Syn monomer (35 *μ*M, 5% w/w seed, 20 *μ*M ThT).](gr2){#fig2}

![Measurement of fibril elongation by QCM. AFM imaging of the (*A*) preparation and (*B*) growth of *α*Syn fibrils on an activated gold surface. (*C*) The effect of *α*B-crystallin on fibril elongation, studied by QCM. Mass loading plot showing mass changes calculated from the (*a*) third, (*b*) fifth, and (*c*) seventh harmonics of the crystal. Arrows indicate injection of 1), 0.25 mg/mL A53T; 2), 0.25 mg/mL A53T plus 0.18 mg/mL *α*B-crystallin; and 3), 0.25 mg/mL A53T, showing approximately sevenfold inhibition of elongation. (*D*) Elongation rates determined in a separate QCM experiment, where *α*Syn monomer was injected at 0.1 mg/mL in the absence or presence of *α*B-crystallin at 0.5 mg/mL, as labeled on the *x* axis. The reaction chamber was flushed with fresh buffer between measurements. As in [Fig. 3](#fig3){ref-type="fig"}*C*, on injection of *α*B-crystallin and *α*Syn, a large increase in mass loading occurred over ∼0.5 h, after which linear growth was observed, and the elongation rate is plotted for this steady-state condition. The final measurement of elongation was performed after overnight incubation of the surface in fresh buffer.](gr3){#fig3}

![Interaction of *α*B-crystallin with *α*Syn fibrils observed by one-dimensional ^1^H NMR spectroscopy. (*A*) Methyl and DSS (resonance at 0 ppm) regions of the one-dimensional ^1^H spectra of 70 *μ*M A53T *α*Syn fibrils complexed with 20 *μ*M *α*B-crystallin, and of the fibrils and chaperone separately. (*B*) Effective diffusion coefficients determined for these samples by PFG NMR experiments using a 500-ms diffusion delay.](gr4){#fig4}

![Immunoelectron microscopy of *α*B-crystallin-*α*Syn fibril complexes. *α*B-Crystallin was labeled with 10-nm gold nanoparticles (*arrows*) as described in [Materials and Methods](#sec2){ref-type="sec"} (see [Supporting Material](#app2){ref-type="sec"}). (*A*) *α*Syn fibrils alone; (*B*) *α*B-crystallin alone; and (*C*) *α*Syn fibrils plus 0.3 equivalence of *α*B-crystallin. All scale bars are 500 nm.](gr5){#fig5}
